Hitting the Bullseye: A Field Guide to Molecular Targets in Cancer

How oncogenes, tumor suppressors, and kinase fusions define the modern precision-oncology playbook — and the drugs built to exploit them

Key Points

Two Ways to Attack a Cancer Cell

Every targeted cancer therapy is built on a single insight: tumors are addicted to specific molecular machinery, and if you can identify that machinery you can design a drug to break it. But cancers cheat in two opposite ways, and the whole field of precision oncology divides cleanly along that line. Targets of activation — the oncogenes. Genes like EGFR, HER2, KRAS, BRAF, and ALK are the accelerator pedals of the cell. When they mutate, amplify, or fuse, they jam the accelerator to the floor and drive relentless proliferation. Here the therapeutic goal is straightforward: turn the…

Receptor Tyrosine Kinases: The Cell-Surface Accelerators

Receptor tyrosine kinases (RTKs) are cell-surface receptors that transmit extracellular growth signals into the cell. Overactivation heavily drives tumor proliferation, which makes them the most heavily targeted class in solid oncology. EGFR (Epidermal Growth Factor Receptor) is the archetype. Primary indications are non-small cell lung cancer (NSCLC), glioblastoma, and colorectal cancer — and here the specific alteration determines the drug. Exon 19 deletions and the exon 21 L858R point mutation are the classic "activating" mutations in NSCLC that confer sensitivity to first-, second-, and…

The MAPK Pathway: The Master Switch for Division

The eCancerMD editorial team mapped out this cascade to serve as a fast switchboard reference: downstream of the RTKs sits the MAPK cascade — KRAS to BRAF to MEK to ERK — which acts as the master switch for cell division. When a component of this pathway is locked on, the cell divides regardless of what the surface receptors are doing. KRAS (Kirsten Rat Sarcoma Viral Oncogene) was for decades the "undruggable" target. Primary indications are colorectal, pancreatic, and non-small cell lung cancer. The G12C mutation is the most heavily targeted point mutation in lung adenocarcinoma, now…

Kinase Fusions: The Always-On Chimeras

Chromosomal rearrangements can fuse a kinase gene to a partner gene, creating an always-on chimeric protein that drives the tumor. These fusions are rare but highly actionable — matched inhibitors often produce dramatic, durable responses. ALK (Anaplastic Lymphoma Kinase) is found mainly in NSCLC, predominantly in never-smokers and younger patients. The EML4-ALK fusion is the most common structural rearrangement and is highly sensitive to next-generation ALK inhibitors like alectinib and lorlatinib. ROS1 and RET are both actionable but present differently by disease. ROS1 fusions occur…

NTRK Fusions: The Poster Child for Tumor-Agnostic Therapy

If kinase fusions like EML4-ALK proved that a rearrangement can define a tumor, NTRK fusions proved that the driver can matter more than the organ it arises in. NTRK1, NTRK2, and NTRK3 encode the TRK family of neurotrophin receptors, and when any of them fuses to a partner gene the result is a constitutively active kinase — regardless of whether the tumor started in the lung, the salivary gland, the thyroid, the colon, or the soft tissue of a child. That tissue-agnostic biology reshaped how the FDA approves drugs. The TRK inhibitors larotrectinib and entrectinib were among the first agents…

FGFR and MET: Two More Druggable Receptor Kinases

Beyond EGFR and HER2, two additional receptor tyrosine kinases have become routine actionable findings — each defined by a very specific alteration that dictates the drug. FGFR (Fibroblast Growth Factor Receptor) alterations are strongly tissue- and paralog-specific. FGFR2 fusions are the defining actionable driver in intrahepatic cholangiocarcinoma, where the FGFR inhibitor pemigatinib (and, in the second line, futibatinib) produces meaningful responses in a cancer with otherwise limited options. FGFR3 alterations — activating mutations and fusions — instead predominate in urothelial…

Beyond Kinases: Targeting Cancer Metabolism with IDH

Not every actionable target is a kinase. IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) are metabolic enzymes, and their mutations broaden precision oncology from the tyrosine-kinase playbook into cancer metabolism and epigenetics. The mechanism is elegant and unusual. Mutant IDH acquires a new ("neomorphic") enzymatic activity that produces an oncometabolite called 2-hydroxyglutarate (2-HG). Accumulating 2-HG poisons the enzymes that normally regulate DNA and histone methylation, blocking cellular differentiation — the cells are frozen in an immature, proliferative state. Inhibiting…

Tumor Suppressors: Turning Loss Into a Vulnerability

Unlike oncogenes, tumor suppressor genes act as the cell's brakes. Cancer shuts them down through deletions or inactivating mutations — and because the protein is lost rather than over-active, the therapeutic logic inverts. PTEN (Phosphatase and Tensin Homolog) is altered across prostate, breast, endometrial, and glioblastoma. Homozygous or heterozygous deletion removes the brakes on the PI3K/AKT/mTOR pathway, leading to unchecked cell survival. PTEN loss is often used as a biomarker for resistance to certain hormone therapies or sensitivity to AKT inhibitors. BRCA1 and BRCA2 drive breast,…

The PI3K/AKT/mTOR Axis: Downstream Survival Signaling

Running parallel to the MAPK proliferation cascade is a second major signaling node — the PI3K/AKT/mTOR pathway — which governs cell survival, growth, and metabolism. It is the pathway that PTEN loss unleashes, and it is drugged directly at several points. PIK3CA (the gene encoding the p110α catalytic subunit of PI3K) is one of the most frequently mutated oncogenes in hormone receptor-positive, HER2-negative breast cancer. Activating PIK3CA mutations switch the survival pathway on, and the PI3K inhibitor alpelisib — given with endocrine therapy — is the matched option for these tumors,…

When Targets Fight Back: The Resistance Framework

Targeted therapy is rarely a permanent cure, because the target itself evolves under selective pressure. Understanding the escape routes is as important as knowing the original driver. Gatekeeper mutations are the first route. The EGFR T790M mutation is the textbook example — a second-site change in the target that physically blocks first-generation drug binding, which is precisely why third-generation agents like osimertinib were engineered to overcome it. Bypass-track activation is the second. A tumor can sidestep a blocked pathway entirely: an EGFR-mutant lung tumor, for instance, may…

Moving Beyond the Genome

If the last decade of oncology was about finding DNA point mutations — the EGFR and KRAS alterations that define a tumor's genome — the next decade is about everything that happens after the mutation. The frontier is no longer just which gene is broken, but how the resulting protein is destroyed, how its RNA is spliced, and how the surrounding immune microenvironment shields the tumor from attack. This matters because the classic strategy — block a protein's active site — only works if the protein has a druggable pocket. Many of oncology's most important drivers are "undruggable"…

Targeted Protein Degradation: The 'Undruggable' Frontier

Traditional drugs block a receptor's active site. If a target lacks a blockable binding pocket, it is labeled "undruggable." Targeted protein degradation flips the logic: instead of blocking the protein, heterobifunctional molecules such as PROTACs (proteolysis-targeting chimeras) hijack the cell's ubiquitin-proteasome system and destroy the target outright. Estrogen receptor (ER) degradation is the proof of concept. Targeting the estrogen receptor is an old idea, but degrading it completely is highly novel. In mid-2026 vepdegestrant became a landmark advance — the first PROTAC to…

Next-Generation Immune Checkpoints

Many patients never respond to traditional PD-1/PD-L1 inhibitors, so immunology research has turned to entirely new cell-surface checkpoints. IGSF8 (Immunoglobulin Superfamily Member 8) is a highly novel checkpoint gaining traction in 2026 preclinical and early phase 1 trials. Identified largely through AI-driven mapping of the tumor microenvironment, IGSF8 blockade disrupts a stealth mechanism tumors use to hide from both T-cells and natural killer (NK) cells. It is being explored as a monotherapy for advanced solid tumors that are completely resistant to conventional immunotherapy. TIGIT…

Alternative RNA Splicing & Neoantigens

Instead of targeting mutated DNA, researchers are increasingly targeting the errors cancer makes when it processes RNA. Using high-throughput AI and computational platforms, they identify neoantigens created when cancer cells mis-splice their RNA. The appeal is specificity: these mis-spliced peptides do not exist on healthy tissue, so they make ideal targets. That opens the door to bespoke mRNA cancer vaccines and engineered cellular therapies customized to a tumor's specific RNA footprint rather than its DNA mutations alone — an approach already being piloted with neoantigen vaccines in…

Oncofetal & Rare Fusion Targets

A final frontier exploits proteins that are highly active during fetal development and then abnormally switched back on by malignant tumors. GPC2 (Glypican-2) is a novel oncofetal antigen highly expressed in aggressive pediatric solid tumors such as neuroblastoma, yet absent from healthy adult tissue. That near-perfect specificity makes GPC2 a leading target for engineered antibody-TCR hybrids and CAR-T cell designs, offering a route to eliminate solid tumors with minimal off-target toxicity. NRG1 (Neuregulin 1) fusions are rare structural rearrangements found across multiple solid tumors,…